对治疗不耐药的自身免疫性结缔组织疾病的双特异性T细胞参与剂
Christina Düsing1,2,3, Andrea-Hermina Györfi1,2,3, Ayla Nadja Stütz1,2
1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany.
Nature medicine
|February 19, 2026
概括
布利纳图莫马布和特克利斯塔马布作为重症抗合成酶综合征 (ASyS) 和全身性硬化症 (SSc) 的救援疗法具有前景. 这些T细胞参与剂 (TCE) 改善了治疗不耐药患者的症状和减少了自身抗体.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
背景情况:
- 抗合成酶综合征 (ASyS) 和全身性硬化症 (SSc) 是自身免疫性疾病,具有重大未满足的医疗需求.
- 治疗耐药病例带来了挑战,需要新的治疗策略.
研究的目的:
- 评估blinatumomab和teclistamab作为治疗不耐治疗ASyS和SSc的同情使用疗法的疗效和安全性.
- 评估这些T细胞参与因子 (TCE) 对疾病标志物,临床结果和不良事件的影响.
主要方法:
- 五名不耐治疗的ASyS患者接受了布利纳图莫马布 (CD19×CD3 TCE).
- 五名治疗不耐药的SSc患者接受了德克利斯塔马布 (BCMA×CD3 TCE).
- 用Rituximab (RTX) 进行维护疗法,以抑制B细胞再分化.
主要成果:
- 在ASyS患者中,BLINATUMOMAB改善了肌肉炎,稳定了间歇性肺病 (ILD),减少了细胞和自身抗体.
- 德克利斯塔马布改善了皮肤纤维化,稳定了ILD,并在SSc患者中解决了肌摩擦摩擦.
- 通过RTX维持,即使在RTX不响应的患者中,也可以实现长时间的疾病控制. 副作用包括细胞因子释放综合征 (CRS) 和呼吸道感染.
结论:
- 布利纳图莫马布和特克利斯塔马布显示出作为耐火性ASyS和SSc的救援疗法的潜力.
- 这些TCE可以诱导临床,血清学和组织学方面的改善.
- 需要进一步的研究来确定它们在管理这些复杂的自身免疫性疾病中的作用.
更多相关视频
相关概念视频
Cell-mediated Immune Responses
Overview
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...


